Viridian Therapeutics, Inc. (VRDN)


+0.29 (+2.44%)
Symbol VRDN
Price $12.19
Beta 1.178
Volume Avg. 0.18M
Market Cap 368.471M
Shares () -
52 Week Range 9.47-22.0
1y Target Est -
DCF Unlevered VRDN DCF ->
DCF Levered VRDN LDCF ->
ROE -52.68% Strong Sell
ROA -47.30% Strong Sell
Operating Margin -
Debt / Equity 9.92% Neutral
P/E -
P/B 0.82 Buy


Consensus EPS

Upgrades & Downgrades

Latest VRDN news

Mr. Jason A. Leverone CPA, CPA
NASDAQ Capital Market

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.